Patents Assigned to Momenta Pharmaceuticals, Inc.
  • Patent number: 9695244
    Abstract: The present invention relates to the characterization and production of denosumab.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: July 4, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: John Robblee, Brian Edward Collins, Ganesh Kaundinya, Carlos J. Bosques
  • Patent number: 9677105
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using ammonium and/or lysine, are described.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 13, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Brian Edward Collins, Holly Prentice, Brett Belongia, Rasheed Tijani
  • Patent number: 9663810
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: May 30, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Patent number: 9663581
    Abstract: Modified glycoproteins, and methods of making and using such modified glycoproteins, are described.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: May 30, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Nathaniel Washburn, James Meador, III, Carlos J. Bosques, Dorota A. Bulik, Naveen Bhatnagar, Julia Brown, Lynn Markowitz, Sathya Prabbhakar
  • Patent number: 9650433
    Abstract: Sulfated glycoproteins, and methods of making and using such sulfated glycoproteins, are described.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: May 16, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Dorota A. Bulik, Carlos J. Bosques, Brian Edward Collins, Maurice Gaston Hains, Nathaniel J. Washburn, James Meador, Sean Smith, Naveen Bhatnagar
  • Publication number: 20170066826
    Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.
    Type: Application
    Filed: April 28, 2016
    Publication date: March 9, 2017
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventors: Carlos J. BOSQUES, James S. HUSTON, Jonathan C. LANSING, Leona E. LING, James MEADOR, III, Daniel ORTIZ, Laura RUTITZKY, Birgit C. SCHULTES
  • Publication number: 20160376624
    Abstract: Polypeptides having target levels of C-terminal variants are described.
    Type: Application
    Filed: September 9, 2016
    Publication date: December 29, 2016
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Patent number: 9487810
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using DMSO, are described.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: November 8, 2016
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Holly Prentice, Rasheed Tijani, Brett Belongia
  • Patent number: 9475858
    Abstract: A method for producing recombinant polypeptides, including antibodies, having targeted levels of carboxyl terminal (C-terminal) lysine or arginine residues is presented. The method involves culturing cells expressing said polypeptides in cell culture medium having sufficient levels of lysine, arginine, and/or agents that change intracellular pH. Culturing the cells under such conditions does not affect cell growth, cell viability, or titer.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: October 25, 2016
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice
  • Patent number: 9448147
    Abstract: A multi-dimensional chromatographic method for the separation of N-glycans. The method comprises providing a glycan preparation that includes at least one negatively charged N-glycan. The glycan preparation is then separated by anion-exchange chromatography and at least one secondary chromatographic technique.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: September 20, 2016
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Ian Christopher Parsons, Ting Zheng, Nur Sibel Gunay, Carlos J. Bosques
  • Publication number: 20160257754
    Abstract: Pharmaceutical preparations containing polypeptides having particular sialylation patterns, and methods for the treatment of immune-related thrombocytopenia with such preparations, are described.
    Type: Application
    Filed: October 14, 2014
    Publication date: September 8, 2016
    Applicant: Momenta Pharmaceuticals Inc.
    Inventors: Birgit C. SCHULTES, Chia Lin CHU, Laura RUTITZKY, Lynn ZHANG, Leona E. LING
  • Patent number: 9410964
    Abstract: Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: August 9, 2016
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Xiangping Zhu, Zachary Shriver, Yanjie Jiang, Corinne Bauer, James Eric Anderson, Peter James Ahern
  • Patent number: 9395374
    Abstract: Methods for analyzing, selecting, characterizing or classifying compositions of a co-polymer, e.g., glatiramer acetate are described. The methods entail analysis of pyro-glutamate in the composition, and, in some methods, comparing the amount of pyro-glutamate present in a composition to a reference standard.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: July 19, 2016
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Xiangping Zhu, Zachary Shriver, Yanjie Jiang, Corinne Bauer, James Eric Anderson, Peter James Ahern
  • Patent number: 9387256
    Abstract: Methods and compositions related to targeting agents to tumor tissue are described.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: July 12, 2016
    Assignee: MOMENTA PHARMACEUTICALS, INC.
    Inventors: He Zhou, Edward Cochran, Takashi Kei Kishimoto
  • Patent number: 9358252
    Abstract: Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: June 7, 2016
    Assignee: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Mallikarjun Sundaram, Takashi Kei Kishimoto, Sucharita Roy
  • Patent number: 9351992
    Abstract: Preparations of polysaccharides lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: May 31, 2016
    Assignee: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Mallikarjun Sundaram, Takashi Kei Kishimoto, Sucharita Roy
  • Publication number: 20160129028
    Abstract: Described herein are pharmaceutical compositions comprising a LMWH preparation having at least one chain having a glycol split uronic acid residue (UG) in the preparation and uses thereof.
    Type: Application
    Filed: May 27, 2014
    Publication date: May 12, 2016
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Kelly Neelon, Gary Mills, James Anderson
  • Publication number: 20160097074
    Abstract: The invention provides methods, databases and systems for making glycoprotein products having defined properties.
    Type: Application
    Filed: October 14, 2015
    Publication date: April 7, 2016
    Applicant: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Brian Edward Collins, Carlos J. Bosques, Lakshmanan Thiruneelakantapillai, Dorota A. Bulik, Ian C. Parsons, Zachary Shriver, Rajeev Chillakuru, Ganesh Kaundinya
  • Publication number: 20150368317
    Abstract: The present disclosure provides, in part, methods for evaluating, identifying, and/or producing (e.g., manufacturing) a CTLA4-Fc fusion protein, e.g., abatacept. In some instances, methods herein allow highly resolved evaluation of abatacept useful for, inter alia, manufacturing abatacept, characterizing abatacept, identifying and/or confirming abatacept, monitoring the structure of abatacept, comparing abatacept preparations made over time or made under different conditions, and/or controlling the structure of abatacept.
    Type: Application
    Filed: May 31, 2013
    Publication date: December 24, 2015
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventors: John ROBBLEE, Xiaomei HE, Yan YIN, Yin Yin LIN, Brian COLLINS, Jennifer MURPHY, Ganesh KAUNDINYA
  • Patent number: 9217168
    Abstract: Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 22, 2015
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventor: Holly Prentice